Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)

February 1, 2024

https://www.globenewswire.com/news-release/2024/02/01/2821881/0/en/Abeona-Therapeutics-Announces-Progress-Update-on-Pz-cel-Biologics-License-Application-BLA.html

– On track for PDUFA target action date of May 25, 2024 –

CLEVELAND, Feb. 01, 2024 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq:ABEO) today announced, as part of the review process by the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for pz-cel (prademagene zamikeracel) for recessive dystrophic epidermolysis bullosa (RDEB), completion by the FDA of both a Bioresearch Monitoring (BIMO) inspection of Abeona and the BLA mid-cycle review meeting.

Read more at globenewswire.com

Related news for (ABEO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.